Clinical Trial Update: Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating intravitreal aflibercept injection for polypoidal choroidal vasculopathy with hemorrhage or exudation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Eylea (aflibercept) (aflibercept)

Snippet

Sponsor: Gregg T. Kokame, MD | Conditions: Polypoidal Choroidal Vasculopathy | Phase 4 | Status: COMPLETED